News Search: More search options


Health: Acrongenomics Inc.
 

Acrongenomics Inc.


Acrongenomics, Inc. is pleased to announce that it has retained KGMC Group, LLC of Frankfort, Illinois to introduce its cutting-edge Nano-JETA™ technology platform to the world market.


[ClickPress, Mon Nov 14 2005] Acrongenomics, Inc. Retains KGMC Group, LLC

Acrongenomics, Inc. is pleased to announce that it has retained KGMC Group, LLC of Frankfort, Illinois to introduce its cutting-edge Nano-JETA™ technology platform to the world market.

Privately-held KGMC Group LLC (www.kgmcgroup.com) introduces and markets advanced medical technologies. With a diverse team of talented and respected professionals in medicine, science, business, finance, marketing and law from four continents, KGMC provides services and solutions essential to converting emerging technologies into viable business ventures. KGMC Group LLC will work with Acrongenomics to complete formal validations of the advanced Nano-JETA™ platform, secure publications of this breakthrough technology in respected medical and scientific journals and identify ideal partners to commercialize the technology.
“Following a year of thorough study, our scientists and Board of Directors have confirmed that Acrongenomics’ know-how in nanotechnology has resulted in compelling breakthroughs, significantly impacting our battle with various diseases such as cancer. We are convinced that Nano-JETA™ technology platform can accelerate and enhance the commonly used Real Time PCR amplification process, so that it is rendered 100% accurate in detecting genetic diseases such as cancer. Neo-EpCAM™ cancer detection assay is the first application utilizing the Nano-JETA™ technology. More so exciting is that the process takes less than two minutes. Because it is fast, inexpensive, easy to administer, non-invasive, accurate, specific and uses existing equipment, we are convinced that the technology will assist physicians in detecting genetic diseases quickly, accurately and early enough to potentially save lives and avoid much cost and anguish. Now confident in the technology, we will assist Acrongenomics in securing a partner to further develop and market such technology.” Says KGMC Group President Bill Kanatas.

Acrongenomics Inc.(www.acrongen.com) (OTCBB:AGNM) is a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics for the Life Sciences Industry. The Company is seeking to establish its proprietary nanotechnology platform as a global standard in Molecular In Vitro Diagnostics.

Acrongenomics has successfully conducted laboratory tests and clinical trials for the cancer detection and quantification process. The technology has been applied to major Molecular Diagnostics techniques such as Polymerase Chain Reaction (PCR) and Real-Time PCR producing outstanding results in terms of sensitivity, reproducibility, specificity and speed with the use of conventional equipment.






Company: Acrongenomics Inc.
Contact Name: Tom Skarpelos
Contact Email: tom@acrongen.com
Contact Phone: +302109859203
Related website
[+] Global news distribution by ClickPress. To manage your News Alerts Subscription, click here. To reach News Alerts subscribers via an Enhanced Distribution, click here.
 

Home | Latest News | Submit News | Advanced Search | About Us | Contact Us | News Alerts Subscribe/Unsubscribe |
Terms and Conditions | Copyright © 2005-2011 ClickPress